Keros Therapeutics downgraded by Cantor Fitzgerald
$KROS
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/21/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 1/17/2025 | $15.00 | Outperform → Neutral | Wedbush |
| 12/16/2024 | $102.00 → $63.00 | Outperform | Oppenheimer |
| 12/16/2024 | Buy → Neutral | Guggenheim | |
| 12/13/2024 | $100.00 → $47.00 | Buy | H.C. Wainwright |
| 12/12/2024 | Buy → Hold | TD Cowen | |
| 12/12/2024 | Outperform → Mkt Perform | William Blair | |
| 12/12/2024 | Buy → Neutral | BTIG Research |
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 10:00 a.m. Eastern time. A live audio webcast of the fireside chat presentation will be available at https://wsw.co
LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the global development and commercialization license agreement with Takeda (NYSE:TAK) to advance elritercept became effective on January 16, 2025. The agreement, which was previously announced on December 3, 2024, became effective upon the expiration or termination of the applicable waiting p
LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review d
Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral
Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00
Oppenheimer reiterated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $63.00 from $102.00 previously
Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patient
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all programs across our pipeline in the second quarter of 2024, as evidenced by our recent positive regulatory and data updates from the elritercept (KER-050) program," said Jasbir S. Seehra, Ph.D
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigueData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scoresKeros will host a corporate update call and webcast today, June 17, 2024, at 8:00 a.m. ET LEXINGTON, Mass., June 17, 2024 (GLOBE NE
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
8-K - Keros Therapeutics, Inc. (0001664710) (Filer)
LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply
LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a
4/A - Keros Therapeutics, Inc. (0001664710) (Issuer)
4 - Keros Therapeutics, Inc. (0001664710) (Issuer)
3 - Keros Therapeutics, Inc. (0001664710) (Issuer)